In a breakthrough moment for accessible technology in India, a team of students from Chandigarh has been awarded a design patent for their innovative invention – GestureX, a pair of smart glasses that can convert spoken language into sign language in real-time. This pioneering project aims to bridge communication gaps for the hearing-impaired, enhancing inclusivity in education, workplaces, and daily life.
Breaking Communication Barriers with Technology
GestureX represents a significant leap in assistive wearable technology. The device is expected to transform how individuals with hearing disabilities interact with the world around them, particularly in environments where sign language interpreters are unavailable.
The patent, granted under Class 16-06 (relating to communication equipment), marks formal recognition of the students’ innovation, positioning GestureX as a potential game-changer in inclusive communication tools.
How GestureX Works
The functionality of GestureX is underpinned by a combination of hardware and software components that work seamlessly together:
Built-in Microphones: The glasses are fitted with directional microphones that capture ambient speech in real-time.
Speech Recognition Engine: Advanced software processes spoken words and converts them into text-based commands.
Sign Language Renderer: A miniature display system integrated into the glasses projects animated sign language gestures that correspond to the recognized speech.
Efficient Power Management: Designed with lightweight battery systems, GestureX ensures portability and extended battery life for regular use.
The glasses have been optimized to recognize multiple accents and background noise, ensuring accuracy in varied environments like classrooms, conferences, or public transport.
Designed by Students, Backed by Innovation
The team behind GestureX comprises students from diverse technical backgrounds who came together with a shared vision to make technology more inclusive. Motivated by personal experiences and community challenges, the team sought to develop a tool that could empower the deaf and hard-of-hearing communities with greater independence and confidence.
According to the team spokesperson, “Our goal was to build something meaningful that could help real people in real situations. GestureX is not just a gadget—it’s a step toward equal access and inclusive communication.”
Broader Implications and Future Development
GestureX’s creators are in discussions with academic institutions and healthcare providers to initiate pilot testing of the device. Early trials will help refine the technology, particularly for use in multilingual settings where regional sign language variants are common.
Looking ahead, the team plans to integrate artificial intelligence to allow the glasses to adapt to individual speech patterns, improve gesture accuracy, and potentially support reverse translation—from sign language to spoken words—to facilitate two-way communication.
They are also exploring partnerships for manufacturing and scaling the product, with the aim of keeping it affordable for individuals and organizations that serve the deaf and hard-of-hearing communities.
A Leap Forward in Assistive Tech
As India continues to promote inclusive innovation through programs like Startup India and the Atal Innovation Mission, projects like GestureX highlight the role of youth-led innovation in solving socially relevant problems. The device stands as a testament to the power of interdisciplinary collaboration and the potential for accessible design to foster greater equity in communication.
If successfully commercialized, GestureX could join the ranks of transformative assistive devices, not only within India but globally, providing a much-needed communication bridge in an increasingly interconnected world.
technology
University of Hyderabad Researchers Secure Patents for Pioneering Innovations in Materials Science
The University of Hyderabad (UoH), one of India’s premier research institutions, continues to solidify its reputation in scientific innovation, with two newly granted patents in the field of materials science and microwave technology.
The patents, awarded to faculty members from the School of Physics and the Advanced Centre of Research in High Energy Materials (ACRHEM), underscore UoH’s growing impact in high-performance materials research with wide-ranging industrial applications.
Innovation in 3D Ceramic Resonators
The first patent, titled “Dielectric Resonators with Complex 3D Geometries Using Gel Casting Techniques,” is credited to Professors K.C. James Raju and V. Seshubai, along with research scholars T. Anil and Swarup Raju. This novel method facilitates the production of high-temperature ceramic dielectric resonators molded into intricate three-dimensional structures.
Traditionally, creating 3D resonators from ceramic materials poses significant challenges due to their brittle nature and high processing temperatures. The patented gel casting approach overcomes these limitations, enabling the fabrication of compact and high-performance resonators suitable for next-generation microwave and millimeter-wave communication systems.
“This technique opens new pathways for designing miniaturized antennas and frequency filters, particularly in 5G and satellite communication devices,” explained Prof. Raju.
Breakthrough in Low-Temperature Crystallization
The second patent focuses on the laser-based crystallization of ferroelectric thin films, a breakthrough that significantly lowers the thermal requirements for these critical materials. Spearheaded again by Prof. K.C. James Raju and his team, the technique successfully reduces the crystallization temperature from 700°C to 300°C by utilizing controlled laser irradiation.
This innovation has significant implications for the electronics industry, particularly in the integration of ferroelectric materials into semiconductor devices, which typically cannot endure high processing temperatures. Lower thermal thresholds enable the application of these films in tunable microwave components, sensors, and energy-efficient electronic devices.
“This development bridges the gap between high-performance ferroelectric materials and practical device manufacturing,” noted Prof. Raju.
UoH’s Growing Patent Portfolio
With these two patents, the University of Hyderabad continues to expand its footprint in applied scientific research and industrial collaboration. The institution has increasingly focused on promoting innovation that addresses real-world challenges in communication, electronics, and advanced materials.
Vice-Chancellor Prof. B.J. Rao praised the research teams for their work, stating, “These achievements are a testament to the University’s commitment to fostering a research environment that supports both theoretical advancement and practical application.”
Looking Ahead
As global industries seek cost-effective and scalable technologies in electronics and telecommunications, the breakthroughs from UoH researchers could play a pivotal role in shaping future solutions. The university also aims to collaborate with industries and startups to bring these patented technologies from the lab to the market.
While the university has yet to announce any patent specifically related to alpha alumina platelets, these recent innovations indicate that UoH remains a leader in cutting-edge materials science research with broad commercial potential.
The patents, awarded to faculty members from the School of Physics and the Advanced Centre of Research in High Energy Materials (ACRHEM), underscore UoH’s growing impact in high-performance materials research with wide-ranging industrial applications.
Innovation in 3D Ceramic Resonators
The first patent, titled “Dielectric Resonators with Complex 3D Geometries Using Gel Casting Techniques,” is credited to Professors K.C. James Raju and V. Seshubai, along with research scholars T. Anil and Swarup Raju. This novel method facilitates the production of high-temperature ceramic dielectric resonators molded into intricate three-dimensional structures.
Traditionally, creating 3D resonators from ceramic materials poses significant challenges due to their brittle nature and high processing temperatures. The patented gel casting approach overcomes these limitations, enabling the fabrication of compact and high-performance resonators suitable for next-generation microwave and millimeter-wave communication systems.
“This technique opens new pathways for designing miniaturized antennas and frequency filters, particularly in 5G and satellite communication devices,” explained Prof. Raju.
Breakthrough in Low-Temperature Crystallization
The second patent focuses on the laser-based crystallization of ferroelectric thin films, a breakthrough that significantly lowers the thermal requirements for these critical materials. Spearheaded again by Prof. K.C. James Raju and his team, the technique successfully reduces the crystallization temperature from 700°C to 300°C by utilizing controlled laser irradiation.
This innovation has significant implications for the electronics industry, particularly in the integration of ferroelectric materials into semiconductor devices, which typically cannot endure high processing temperatures. Lower thermal thresholds enable the application of these films in tunable microwave components, sensors, and energy-efficient electronic devices.
“This development bridges the gap between high-performance ferroelectric materials and practical device manufacturing,” noted Prof. Raju.
UoH’s Growing Patent Portfolio
With these two patents, the University of Hyderabad continues to expand its footprint in applied scientific research and industrial collaboration. The institution has increasingly focused on promoting innovation that addresses real-world challenges in communication, electronics, and advanced materials.
Vice-Chancellor Prof. B.J. Rao praised the research teams for their work, stating, “These achievements are a testament to the University’s commitment to fostering a research environment that supports both theoretical advancement and practical application.”
Looking Ahead
As global industries seek cost-effective and scalable technologies in electronics and telecommunications, the breakthroughs from UoH researchers could play a pivotal role in shaping future solutions. The university also aims to collaborate with industries and startups to bring these patented technologies from the lab to the market.
While the university has yet to announce any patent specifically related to alpha alumina platelets, these recent innovations indicate that UoH remains a leader in cutting-edge materials science research with broad commercial potential.
Donald Trump Urged to Target ‘Lazy Patent Expansion’ in U.S. Drug Bill Push
In a significant development in the ongoing debate over U.S. drug pricing, Richard Saynor, CEO of Sandoz, a leading generic pharmaceutical company, has called on former President Donald Trump to address the issue of “lazy patent expansion” in his efforts to reduce prescription drug costs. Saynor’s remarks come as Trump seeks to implement a “most favored nation” policy, aiming to align U.S. drug prices of other nations. While supporting this initiative, Saynor emphasized the need for reform in the generics market to ensure sustainable access to affordable medications.
The Problem: Patent Thickets and Evergreening
Saynor criticized the practice of “evergreening,” where brand-name drug manufacturers file numerous patents on slight modifications of existing drugs to extend their market exclusivity. This strategy, often referred to as creating “patent thickets,” has been used to delay the entry of generic competitors, thereby maintaining high drug prices. For instance, blockbuster drugs like AbbVie’s Humira have been subject to extensive patent filings, with over 140 patents filed per top-selling drug, causing prices to remain high and limiting competition.
Impact on Generic Drug Market
Generic drugs account for approximately 90% of prescriptions in the U.S. and are significantly more affordable than their branded counterparts. However, the proliferation of patent thickets has led to shortages and limited availability of generics. Saynor highlighted that the rebate system, which involves pharmacy benefit managers, further inflates drug costs, making it more challenging for generics to compete.
Proposed Solutions
To address these issues, Saynor advocated for reinstating a six-month exclusivity period for first-to-market generics, a policy that could incentivize the development and availability of affordable alternatives. Additionally, he cautioned against proposed pharmaceutical tariffs, which could disproportionately impact generics due to their low margins and reliance on overseas production.
Legislative Efforts and Challenges
Bipartisan efforts to reform the patent system have been introduced in Congress, targeting practices like patent thickets, product hopping, and pay-for-delay agreements. Despite strong support, these bills have faced obstacles in becoming law, often due to legislative gridlock and opposition from industry stakeholders.
Global Implications
Trump’s “most favored nation” policy, which seeks to align U.S. drug prices with those paid by other countries, has raised concerns internationally. In the UK, for example, where branded drugs cost significantly less than in the U.S., pharmaceutical firms may respond by raising prices elsewhere or withholding drugs from certain markets. This could strain healthcare systems globally and potentially discourage pharmaceutical innovation.
Conclusion
As the U.S. continues to grapple with high drug prices, addressing the issue of “lazy patent expansion” is crucial for fostering a competitive and affordable pharmaceutical market. While Trump’s policy initiatives aim to reduce costs, comprehensive reform of the patent system is necessary to ensure long-term access to essential medications for all Americans.
The Problem: Patent Thickets and Evergreening
Saynor criticized the practice of “evergreening,” where brand-name drug manufacturers file numerous patents on slight modifications of existing drugs to extend their market exclusivity. This strategy, often referred to as creating “patent thickets,” has been used to delay the entry of generic competitors, thereby maintaining high drug prices. For instance, blockbuster drugs like AbbVie’s Humira have been subject to extensive patent filings, with over 140 patents filed per top-selling drug, causing prices to remain high and limiting competition.
Impact on Generic Drug Market
Generic drugs account for approximately 90% of prescriptions in the U.S. and are significantly more affordable than their branded counterparts. However, the proliferation of patent thickets has led to shortages and limited availability of generics. Saynor highlighted that the rebate system, which involves pharmacy benefit managers, further inflates drug costs, making it more challenging for generics to compete.
Proposed Solutions
To address these issues, Saynor advocated for reinstating a six-month exclusivity period for first-to-market generics, a policy that could incentivize the development and availability of affordable alternatives. Additionally, he cautioned against proposed pharmaceutical tariffs, which could disproportionately impact generics due to their low margins and reliance on overseas production.
Legislative Efforts and Challenges
Bipartisan efforts to reform the patent system have been introduced in Congress, targeting practices like patent thickets, product hopping, and pay-for-delay agreements. Despite strong support, these bills have faced obstacles in becoming law, often due to legislative gridlock and opposition from industry stakeholders.
Global Implications
Trump’s “most favored nation” policy, which seeks to align U.S. drug prices with those paid by other countries, has raised concerns internationally. In the UK, for example, where branded drugs cost significantly less than in the U.S., pharmaceutical firms may respond by raising prices elsewhere or withholding drugs from certain markets. This could strain healthcare systems globally and potentially discourage pharmaceutical innovation.
Conclusion
As the U.S. continues to grapple with high drug prices, addressing the issue of “lazy patent expansion” is crucial for fostering a competitive and affordable pharmaceutical market. While Trump’s policy initiatives aim to reduce costs, comprehensive reform of the patent system is necessary to ensure long-term access to essential medications for all Americans.
Maruti Suzuki e-Vitara Patented in India; Launch Scheduled for September 2025
Maruti Suzuki has officially patented its upcoming electric SUV, the e-Vitara, in India, marking a significant step towards its anticipated launch in September 2025. This move positions Maruti Suzuki to compete in the rapidly expanding electric vehicle (EV) market in India.
Design and Platform
The e-Vitara is built on the Heartect-e platform, a collaboration between Suzuki and Toyota. This platform integrates eAxles, combining the motor and inverter into a single unit, enhancing efficiency and performance. The SUV features a rugged design with elements like 3-point Matrix LED DRLs, rear lamps, 18-inch alloy wheels, and active air vents at the front to improve aerodynamics .
Battery Options and Range
Maruti Suzuki offers two battery pack options, the larger 61 kWh battery is expected to provide a range of over 500 km on a single charge, making it competitive in its segment .
Interior Features
Inside, the e-Vitara boasts a modern cabin with a 10.25-inch instrument cluster, ambient lighting, a floating center console, a wireless charging pad, and a panoramic glass roof. The SUV also offers a 10-way electrically adjustable driver’s seat and a 40:20:40 split rear seat configuration, enhancing comfort and practicality .
Safety and Technology
Safety features include seven airbags as standard across all variants, a 360-degree camera, and a suite of Advanced Driver Assistance Systems (ADAS). These features aim to provide a high level of safety for occupants .
Pricing and Launch Details
The e-Vitara is expected to be priced competitively, with the base 49 kWh variant starting around ₹20 lakh (ex-showroom). The 61 kWh variant could be priced at approximately ₹25 lakh, while the AllGrip-e AWD model may approach ₹30 lakh . Production is set to commence at Maruti’s Gujarat plant, with exports planned to over 100 countries, including Europe and Japan .
Competitors in the Indian Market
Upon launch, the Maruti Suzuki e-Vitara will compete against several established and upcoming electric SUVs in India, including:
Tata Curvv EV: Expected to be priced between ₹17.49 lakh and ₹22.24 lakh .
Mahindra BE 6: Priced at ₹18.90 lakh .
Hyundai Creta Electric: Expected to be priced between ₹17.99 lakh and ₹24.38 lakh .
MG ZS EV: Priced between ₹18.98 lakh and ₹26.64 lakh .
With its competitive pricing, advanced features, and robust performance, the Maruti Suzuki e-Vitara is poised to be a strong contender in the Indian electric SUV market.
Design and Platform
The e-Vitara is built on the Heartect-e platform, a collaboration between Suzuki and Toyota. This platform integrates eAxles, combining the motor and inverter into a single unit, enhancing efficiency and performance. The SUV features a rugged design with elements like 3-point Matrix LED DRLs, rear lamps, 18-inch alloy wheels, and active air vents at the front to improve aerodynamics .
Battery Options and Range
Maruti Suzuki offers two battery pack options, the larger 61 kWh battery is expected to provide a range of over 500 km on a single charge, making it competitive in its segment .
Interior Features
Inside, the e-Vitara boasts a modern cabin with a 10.25-inch instrument cluster, ambient lighting, a floating center console, a wireless charging pad, and a panoramic glass roof. The SUV also offers a 10-way electrically adjustable driver’s seat and a 40:20:40 split rear seat configuration, enhancing comfort and practicality .
Safety and Technology
Safety features include seven airbags as standard across all variants, a 360-degree camera, and a suite of Advanced Driver Assistance Systems (ADAS). These features aim to provide a high level of safety for occupants .
Pricing and Launch Details
The e-Vitara is expected to be priced competitively, with the base 49 kWh variant starting around ₹20 lakh (ex-showroom). The 61 kWh variant could be priced at approximately ₹25 lakh, while the AllGrip-e AWD model may approach ₹30 lakh . Production is set to commence at Maruti’s Gujarat plant, with exports planned to over 100 countries, including Europe and Japan .
Competitors in the Indian Market
Upon launch, the Maruti Suzuki e-Vitara will compete against several established and upcoming electric SUVs in India, including:
Tata Curvv EV: Expected to be priced between ₹17.49 lakh and ₹22.24 lakh .
Mahindra BE 6: Priced at ₹18.90 lakh .
Hyundai Creta Electric: Expected to be priced between ₹17.99 lakh and ₹24.38 lakh .
MG ZS EV: Priced between ₹18.98 lakh and ₹26.64 lakh .
With its competitive pricing, advanced features, and robust performance, the Maruti Suzuki e-Vitara is poised to be a strong contender in the Indian electric SUV market.
Delhi High Court Clarifies Patent Law Standards in Landmark Ruling on Section 3(d) of the Indian Patents Act, 1970
In a landmark judgment, the Delhi High Court has provided critical clarity on the interpretation and application of Section 3(d) of the Indian Patents Act, 1970, particularly in cases concerning pharmaceutical innovations. The decision, rendered in the matter of Ischemix LLC v. The Controller of Patents, emphasizes the standards of patentability and the admissibility of post-filing data in applications involving new forms of known substances.
Section 3(d): A Barrier to Evergreening
Section 3(d) of the Indian Patents Act is a unique provision designed to prevent the “evergreening” of patents—where pharmaceutical companies attempt to extend patent monopolies by making minor modifications to known substances. The provision stipulates that a new form of a known substance is patentable only if it results in a significant enhancement of efficacy. In the context of pharmaceutical inventions, the Supreme Court, in its 2013 ruling in Novartis AG v. Union of India, interpreted “efficacy” to mean “therapeutic efficacy.”
The Ischemix LLC Case: Background
Ischemix LLC filed an appeal against the rejection of its patent application (No. 9739/DELNP/2011) by the Indian Patent Office on the grounds of Section 3(d). The applicant argued that they had submitted robust data—spanning in-vitro, in-vivo, and clinical trial results—along with expert opinions to demonstrate the enhanced therapeutic efficacy of the compound.
The Patent Office, however, rejected the application, noting that while comparative data had been submitted after the oral hearing, the data was not clearly explained or sufficiently correlated to therapeutic enhancement as claimed in the specification.
High Court’s Ruling: Key Takeaways
1. Therapeutic Efficacy as the Benchmark
The Delhi High Court reaffirmed the principle established in Novartis AG v. Union of India—that efficacy in the context of pharmaceutical patents must be understood as therapeutic efficacy. Mere improvements in physicochemical properties like stability or solubility are insufficient unless they translate to demonstrable therapeutic benefits.
2. Comparative Data: A Necessary Requirement
Drawing from its earlier ruling in DS Biopharma Limited v. Controller of Patents, the Court stressed that applicants must furnish comparative efficacy data to demonstrate enhancement over known substances. Importantly, this data should be provided in the form of structured comparative tables and supported by appropriate scientific evidence.
3. Admissibility of Post-Filing Data
The Court recognized the inherent delay in generating empirical efficacy data, especially in the pharmaceutical sector where clinical trials are time-intensive. It ruled that while some indication of efficacy should be included at the time of filing, post-filing data may be considered if it corroborates the technical effects disclosed in the original specification. This position is consistent with the Calcutta High Court’s judgment in Oyster Point Pharma Inc. v. Controller of Patents, which acknowledged the prolonged timeline for drug development.
4. Timing and Explanation of Additional Data
The Court made it clear that post-filing data must be submitted well before the final hearing at the Patent Office and should be clearly explained. Submitting complex efficacy data during written submissions post-hearing without oral explanation could render it ineffective, as the Controller may struggle to appreciate the technical details.
5. Requirement for Correlation with Specification
Referring to AstraZeneca AB v. Intas Pharmaceuticals Ltd., the Court ruled that post-filing data should only confirm technical effects already hinted at or described in the specification. It cannot be used to introduce an entirely new technical effect.
Court’s Direction in Ischemix Case
Recognizing the importance of the data but noting the lack of explanation linking the data to therapeutic efficacy, the Court directed Ischemix LLC to submit an explanatory note correlating the submitted evidence to enhanced efficacy. Upon the Patent Office’s consent, the Court remanded the application for re-examination, thereby allowing a fair opportunity for reconsideration.
Broader Implications for Patent Law
This judgment offers significant guidance to pharmaceutical companies and patent practitioners navigating Section 3(d). It strikes a delicate balance between encouraging genuine innovation and preventing the misuse of the patent system to monopolize marginal improvements. The judgment also reinforces procedural discipline, requiring that critical data be timely, complete, and clearly presented.
Conclusion
The Delhi High Court’s decision in Ischemix LLC v. The Controller of Patents builds upon the jurisprudence laid down in Novartis and contributes to a growing body of case law interpreting Section 3(d). As patent litigation continues to evolve in India’s dynamic pharmaceutical sector, such decisions will serve as important references for determining the scope of patentable subject matter and the treatment of post-filing evidence.
Legal experts expect that the continued engagement of the judiciary with Section 3(d) will bring greater predictability and transparency to India’s patent system, particularly for drug-related inventions.
Section 3(d): A Barrier to Evergreening
Section 3(d) of the Indian Patents Act is a unique provision designed to prevent the “evergreening” of patents—where pharmaceutical companies attempt to extend patent monopolies by making minor modifications to known substances. The provision stipulates that a new form of a known substance is patentable only if it results in a significant enhancement of efficacy. In the context of pharmaceutical inventions, the Supreme Court, in its 2013 ruling in Novartis AG v. Union of India, interpreted “efficacy” to mean “therapeutic efficacy.”
The Ischemix LLC Case: Background
Ischemix LLC filed an appeal against the rejection of its patent application (No. 9739/DELNP/2011) by the Indian Patent Office on the grounds of Section 3(d). The applicant argued that they had submitted robust data—spanning in-vitro, in-vivo, and clinical trial results—along with expert opinions to demonstrate the enhanced therapeutic efficacy of the compound.
The Patent Office, however, rejected the application, noting that while comparative data had been submitted after the oral hearing, the data was not clearly explained or sufficiently correlated to therapeutic enhancement as claimed in the specification.
High Court’s Ruling: Key Takeaways
1. Therapeutic Efficacy as the Benchmark
The Delhi High Court reaffirmed the principle established in Novartis AG v. Union of India—that efficacy in the context of pharmaceutical patents must be understood as therapeutic efficacy. Mere improvements in physicochemical properties like stability or solubility are insufficient unless they translate to demonstrable therapeutic benefits.
2. Comparative Data: A Necessary Requirement
Drawing from its earlier ruling in DS Biopharma Limited v. Controller of Patents, the Court stressed that applicants must furnish comparative efficacy data to demonstrate enhancement over known substances. Importantly, this data should be provided in the form of structured comparative tables and supported by appropriate scientific evidence.
3. Admissibility of Post-Filing Data
The Court recognized the inherent delay in generating empirical efficacy data, especially in the pharmaceutical sector where clinical trials are time-intensive. It ruled that while some indication of efficacy should be included at the time of filing, post-filing data may be considered if it corroborates the technical effects disclosed in the original specification. This position is consistent with the Calcutta High Court’s judgment in Oyster Point Pharma Inc. v. Controller of Patents, which acknowledged the prolonged timeline for drug development.
4. Timing and Explanation of Additional Data
The Court made it clear that post-filing data must be submitted well before the final hearing at the Patent Office and should be clearly explained. Submitting complex efficacy data during written submissions post-hearing without oral explanation could render it ineffective, as the Controller may struggle to appreciate the technical details.
5. Requirement for Correlation with Specification
Referring to AstraZeneca AB v. Intas Pharmaceuticals Ltd., the Court ruled that post-filing data should only confirm technical effects already hinted at or described in the specification. It cannot be used to introduce an entirely new technical effect.
Court’s Direction in Ischemix Case
Recognizing the importance of the data but noting the lack of explanation linking the data to therapeutic efficacy, the Court directed Ischemix LLC to submit an explanatory note correlating the submitted evidence to enhanced efficacy. Upon the Patent Office’s consent, the Court remanded the application for re-examination, thereby allowing a fair opportunity for reconsideration.
Broader Implications for Patent Law
This judgment offers significant guidance to pharmaceutical companies and patent practitioners navigating Section 3(d). It strikes a delicate balance between encouraging genuine innovation and preventing the misuse of the patent system to monopolize marginal improvements. The judgment also reinforces procedural discipline, requiring that critical data be timely, complete, and clearly presented.
Conclusion
The Delhi High Court’s decision in Ischemix LLC v. The Controller of Patents builds upon the jurisprudence laid down in Novartis and contributes to a growing body of case law interpreting Section 3(d). As patent litigation continues to evolve in India’s dynamic pharmaceutical sector, such decisions will serve as important references for determining the scope of patentable subject matter and the treatment of post-filing evidence.
Legal experts expect that the continued engagement of the judiciary with Section 3(d) will bring greater predictability and transparency to India’s patent system, particularly for drug-related inventions.
India Breaks into Top Six Globally in 6G Patent Filings: MoS Telecom
India has achieved a significant milestone in the global race for next-generation wireless technology by ranking among the top six nations in 6G patent filings. This advancement underscores the country’s growing influence in shaping the future of telecommunications.
Strategic Push for 6G Leadership
Under the ‘Bharat 6G Vision,’ India aims to become a leader in the design, development, and deployment of 6G technology by 2030. The government is actively supporting this initiative through various programs, including funding research and development, establishing testbeds, and fostering collaborations between academia and industry. These efforts are expected to contribute to India’s goal of securing a 10% share of global 6G patents and one-sixth of contributions to global standards within the next three years .
Terahertz Frequency Bands: The Heart of 6G Innovation
6G technology is set to revolutionize wireless communication by operating in terahertz (THz) frequency bands, specifically between 95 GHz and 3 THz. This spectrum allows for data rates up to 1 terabit per second, marking a hundredfold increase over 5G speeds. Such capabilities will enable applications like immersive extended reality, digital twins, and seamless integration of terrestrial and non-terrestrial networks .
To facilitate research and development in these high-frequency bands, the Telecom Regulatory Authority of India (TRAI) has recommended setting up experimental authorizations for operations in the THz spectrum. This move is expected to position India as a global hub for 6G R&D .
Collaborative Efforts and Future Outlook
India’s ascent in 6G patent filings is attributed to a combination of government initiatives, private sector investments, and academic collaborations. Telecom giants like Reliance Jio, Bharti Airtel, and Tata Communications are investing heavily in 6G research, establishing research centers, and forming international partnerships to drive innovation .
Looking ahead, India is set to host the World Telecommunications Standardisation Assembly (WTSA) in Delhi from October 14 to 24, 2024.
Conclusion
India’s entry into the top six nations for 6G patent filings signifies a strategic leap towards becoming a global leader in next-generation wireless technology. With continued investment in research, infrastructure, and international collaboration, India is poised to play a pivotal role in defining the future of telecommunications.
Strategic Push for 6G Leadership
Under the ‘Bharat 6G Vision,’ India aims to become a leader in the design, development, and deployment of 6G technology by 2030. The government is actively supporting this initiative through various programs, including funding research and development, establishing testbeds, and fostering collaborations between academia and industry. These efforts are expected to contribute to India’s goal of securing a 10% share of global 6G patents and one-sixth of contributions to global standards within the next three years .
Terahertz Frequency Bands: The Heart of 6G Innovation
6G technology is set to revolutionize wireless communication by operating in terahertz (THz) frequency bands, specifically between 95 GHz and 3 THz. This spectrum allows for data rates up to 1 terabit per second, marking a hundredfold increase over 5G speeds. Such capabilities will enable applications like immersive extended reality, digital twins, and seamless integration of terrestrial and non-terrestrial networks .
To facilitate research and development in these high-frequency bands, the Telecom Regulatory Authority of India (TRAI) has recommended setting up experimental authorizations for operations in the THz spectrum. This move is expected to position India as a global hub for 6G R&D .
Collaborative Efforts and Future Outlook
India’s ascent in 6G patent filings is attributed to a combination of government initiatives, private sector investments, and academic collaborations. Telecom giants like Reliance Jio, Bharti Airtel, and Tata Communications are investing heavily in 6G research, establishing research centers, and forming international partnerships to drive innovation .
Looking ahead, India is set to host the World Telecommunications Standardisation Assembly (WTSA) in Delhi from October 14 to 24, 2024.
Conclusion
India’s entry into the top six nations for 6G patent filings signifies a strategic leap towards becoming a global leader in next-generation wireless technology. With continued investment in research, infrastructure, and international collaboration, India is poised to play a pivotal role in defining the future of telecommunications.
Delhi High Court Grants Relief to Indian Businessman in ‘ELFY’ Trademark Dispute with Pakistani National
In a significant ruling, the Delhi High Court has granted relief to an Indian businessman in a trademark dispute involving the mark ‘ELFY’ against Pakistani national Mohammed Younus Sheikh. The court’s decision underscores the importance of protecting intellectual property rights and upholding fair business practices.
Background of the Case
The dispute centers around the use of the ‘ELFY’ trademark, which the Indian businessman claims to have developed and used in commerce for several years. Mohammed Younus Sheikh, a Pakistani national, had claimed that his company had been using the ‘ELFY’ mark for industrial adhesives since 1981. Sheikh’s company had registered the mark in Pakistan and asserted that it had acquired a transborder reputation, particularly in India.
The Indian businessman contended that he had been using the ‘ELFY’ mark in India since 1988 and had built a significant reputation and goodwill associated with the mark. He argued that Sheikh’s adoption of the same mark in India was likely to cause confusion among consumers and harm his business interests.
Court’s Findings
The Delhi High Court examined the evidence presented by both parties, including the dates of adoption and use of the ‘ELFY’ mark, marketing materials, and consumer testimonials. The court found that the Indian businessman had established prior use of the mark in India and had built a recognizable brand associated with ‘ELFY.’
In contrast, the court noted that Mohammed Younus Sheikh had not provided sufficient evidence to demonstrate prior use or registration of the ‘ELFY’ mark in India. The court emphasized the principle of territoriality in trademark law, asserting that the rights to a trademark are generally confined to the jurisdiction where the mark is used and recognized.
Legal Implications
This ruling reinforces the importance of establishing and maintaining clear records of trademark use and registration. It also highlights the challenges businesses may face when operating in international markets, where the risk of trademark disputes can arise due to similarities in branding.
Legal experts suggest that businesses should conduct thorough trademark searches before adopting new marks and consider registering their trademarks in key markets to protect their brand identity and prevent potential conflicts.
Conclusion
The Delhi High Court’s decision serves as a reminder of the complexities involved in trademark law and the need for businesses to be vigilant in protecting their intellectual property. As global commerce continues to expand, understanding and navigating trademark rights across different jurisdictions will be crucial for businesses seeking to safeguard their brands.
IIIT-Bangalore Hosts Patent Workshop to Boost Academic Innovation
In a significant move to strengthen the intellectual property (IP) landscape within Karnataka’s academic institutions, the International Institute of Information Technology Bangalore (IIIT-B) organized a one-day workshop titled “Patent Proficiency for Academic Innovators.” The event, held under the New Age Innovation Network (NAIN) 2.0 program, aimed to equip students, faculty, and innovators with practical knowledge on innovation.
Empowering Academic Innovators
The workshop was conducted in collaboration with Startup Karnataka and the Department of IT, BT, Government of Karnataka. Distinguished speakers included Nithin Chakki, KAS, General Manager of the Karnataka Innovation and Technology Society (KITS); Cmd. Sridhar, Registrar of IIIT-B; Prakash Balekundri, CEO of Unique Patent Solutions. They emphasized the critical role of intellectual property rights (IPR) in translating academic research into market-ready solutions.
The sessions provided attendees with insights into identifying patentable ideas, navigating the patent filing process, and enhancing the quality of patent applications. Real-world case studies and expert guidance were integral to the workshop, offering participants a comprehensive understanding of the journey from research ideation to securing intellectual property.
Extending Reach to Tier-2 Institutions
As an anchor institute for the NAIN 2.0 program, IIIT-B extended the workshop’s benefits to several affiliated institutions, including Jain (Deemed-to-be University), Bapuji Institute of Engineering & Technology in Davangere, Malnad College of Engineering, Mangalore Institute of Technology and Engineering, and St. Philomena College in Puttur. This initiative reflects a growing commitment among Tier-2 city institutions to build robust IPR ecosystems and contribute to the state’s innovation goals.
Fostering a Culture of Innovation
Dr. Lakshmi Jagannathan stressed the importance of guiding these innovators in protecting their work, commercializing it, and contributing meaningfully to the economy. The workshop also focused on strengthening the capabilities of Technology Transfer Offices (TTOs) within institutions, emphasizing their role in bridging the gap between innovative ideas and IP protection.
About IIIT-Bangalore and Its Innovation Centre
The IIIT-B Innovation Centre serves as a dynamic hub for fostering innovation, entrepreneurship, and cutting-edge research. As a not-for-profit Section 8 company hosted by IIIT-Bangalore, the centre offers state-of-the-art incubation facilities, advanced labs, and access to expert mentorship. It supports projects across various domains, including artificial intelligence, data science, Internet of Things (IoT), and digital health. Having supported over 100 startups, the centre plays a pivotal role in nurturing emerging talent and driving technological advancements, positioning itself as a key enabler of innovation and collaboration in India’s tech ecosystem.
IIIT-Bangalore, Situated in the heart of Electronic City, Bangalore, it holds a prominent position in the academic landscape and is graded A+ by the National Assessment and Accreditation Council (NAAC).
The successful execution of the “Patent Proficiency for Academic Innovators” workshop marks a significant step forward in Karnataka’s vision to cultivate a knowledge-led innovation economy, ensuring that academic discoveries translate into impactful, real-world solutions.
Vedanta Aluminium Secures Patent for Breakthrough Graphite Recovery Technology on National Technology Day 2025
In a landmark achievement announced on National Technology Day 2025, Vedanta Aluminium, India’s largest aluminium producer, revealed that it has been granted a patent for a pioneering technology that enables the recovery of graphite with over 99% purity from aluminium production waste. This breakthrough positions the company—and the country—at the forefront of sustainable manufacturing and critical mineral independence.
Turning Waste into Strategic Wealth
Reflecting this year’s theme, ‘YANTRA – Yugantar for Advancing New Technology, Research & Acceleration’, Vedanta’s patented innovation transforms industrial waste into a high-value resource, exemplifying the ethos of circular economy and deep-tech advancement.
The technology recovers battery-grade graphite from two hazardous waste streams in aluminium production—Spent Pot Lining (SPL) and Shot Blast Dust. These materials, previously considered non-recoverable and environmentally challenging, are now being repurposed into a strategic asset critical for India’s clean energy future.
A Critical Boost for India’s Mineral Security
The graphite recovered through this technology exhibits exceptional electrical conductivity and robust structural properties, making it ideally suited for use in lithium-ion batteries. Its atomic structure supports efficient lithiation and de-lithiation cycles, which are essential for energy storage systems in electric vehicles, renewable energy integration, and consumer electronics.
The new technology has the potential to significantly reduce this dependency. As one of the top three graphite importers in the Asia-Pacific region—alongside South Korea and Japan—India now has an opportunity to become self-reliant in this critical mineral segment.
Driving Sustainable Innovation
The achievement is emblematic of a larger shift in Indian industry toward innovation-led sustainability. By unlocking new value from what was once waste, Vedanta Aluminium is setting a precedent for responsible industrial practices that support both economic growth and environmental stewardship.
The company’s graphite recovery initiative also contributes to global climate goals by enabling cleaner energy technologies while reducing the environmental burden of industrial waste. It represents a scalable, replicable model for circular economy integration in heavy industry.
Looking Ahead
As India accelerates its transition to a green and self-reliant economy, innovations like Vedanta’s graphite recovery technology will play a critical role in bridging the gap between sustainability and industrial competitiveness. The patent marks not just a technological breakthrough, but a strategic leap toward a cleaner, more resilient future for India.
FEG Global Secures Patent for Innovative Emissions Scrubber, Eyes UK and European Expansion
An innovative engineering firm specializing in industrial equipment for the food manufacturing sector is set to expand its footprint across the UK and Europe after receiving full patent approval for its breakthrough emissions control product.
FEG Global, headquartered in Washington, UK, has developed the LGC Scrubber, a patented system designed to revolutionize odour and oil mist management in food production facilities. The technology is aimed at companies involved in high-temperature frying, cooking, coating, or seasoning—common in seafood, meat, poultry, ready meals, and snack food manufacturing.
The LGC Scrubber features a dual-function system that combines a particulate wet scrubber and a gas scrubber. This allows it to effectively capture and eliminate both oil mist and volatile odour compounds from industrial food processing operations. Its modular design makes it adaptable for integration into existing factory layouts, providing a practical and scalable solution for food manufacturers.
One of the standout benefits of the LGC Scrubber is its potential contribution to the circular economy. The system allows for the collection and possible repurposing of waste emissions—such as oil particles—as biofuel, opening up additional revenue streams for users.
Following the patent approval, FEG Global plans to ramp up sales and installations of the LGC Scrubber across European markets. The company already operates regional offices in the Midlands, Glasgow, and Belgium, positioning it strategically for cross-border growth.
Chris Williams, Managing Director of FEG Global, emphasized the broader impact of the innovation:
The LGC Scrubber is not just a technical achievement; it’s a practical, market-ready solution that addresses critical environmental and operational challenges for food manufacturers. As housing developments increasingly encroach on industrial zones, managing odours and emissions isn’t just good practice—it’s essential for regulatory compliance and community relations.”
The system has already been successfully implemented by Whitby Seafoods, one of the UK’s largest seafood processors known for its iconic Whitby Scampi. The company, which processes over 3,000 tonnes of scampi annually, required a reliable system to manage odours in its high-temperature production environment.
Chris Dickinson, Head of Engineering at Whitby Seafoods, praised the partnership:
“We needed a solution that met our environmental standards while integrating seamlessly into our operational setup. FEG Global delivered exactly that. The LGC Scrubber installation has allowed us to maintain high production volumes while ensuring we continue to meet our environmental responsibilities as a local employer and good neighbour.”
As regulatory pressures mount and community awareness grows around industrial emissions, FEG Global’s LGC Scrubber is poised to become a critical solution for food manufacturers seeking to future-proof their operations while maintaining environmental stewardship.